Share on StockTwits

PDL BioPharma (NASDAQ:PDLI) will post its Q413 quarterly earnings results on Monday, March 3rd. Analysts expect PDL BioPharma to post earnings of $0.43 per share and revenue of $115.22 million for the quarter.

Shares of PDL BioPharma (NASDAQ:PDLI) opened at 8.82 on Friday. PDL BioPharma has a 52-week low of $6.82 and a 52-week high of $10.21. The stock’s 50-day moving average is $8.70 and its 200-day moving average is $8.39. The company has a market cap of $1.235 billion and a P/E ratio of 5.23. PDL BioPharma also was the recipient of a large decrease in short interest during the month of January. As of February 14th, there was short interest totalling 27,234,486 shares, a decrease of 17.2% from the January 31st total of 32,909,146 shares. Currently, 21.2% of the shares of the stock are sold short. Based on an average daily volume of 4,234,405 shares, the short-interest ratio is currently 6.4 days.

The company also recently announced a quarterly dividend, which is scheduled for Friday, September 12th. Shareholders of record on Friday, September 5th will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 6.80%. The ex-dividend date is Wednesday, September 3rd.

On the ratings front, analysts at Zacks reiterated a “neutral” rating on shares of PDL BioPharma in a research note on Friday, January 3rd. They now have a $9.00 price target on the stock.

PDL BioPharma, Inc (NASDAQ:PDLI) is a is a biotech company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.